Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response
Oncotarget - United States
doi 10.18632/oncotarget.4076
Full Text
Open PDFAbstract
Available in full text
Categories
Date
June 3, 2015
Authors
Publisher
Impact Journals, LLC